ArticleBMC medical informatics and decision making2025
Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?
Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical impact of a multidisciplinary remote-based hybrid antibiotic stewardship program in critically ill patients during COVID-19 pandemic in Korea: a prospective pilot implementation study.Antimicrobial resistance and infection control · 2026Article
- Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer patients receiving targeted therapies need to prevent QTc prolongation and life-threatening cardiovascular (CV) events to maintain a balanced benefit-risk ratio. This study aimed to develop an optimal prediction model for QTc prolongation risk and estimate its risk probability in cancer patients treated with oral tyrosine kinase inhibitors (TKIs).
methodsThis retrospective cohort study analyzed electronic medical records (EMR) of cancer patients newly treated with commonly used oral TKIs at a medical center between January 2016 and December 2020. QTc prolongation was defined as ≥ 450 ms in males and ≥ 470 ms in females using Bazett's formula. The study followed four key steps: (1) Managing missing data, (2) Identifying important variables, (3) Training and testing the best prediction models, (4). Estimating risk probability and determining cut-off points. Both univariate logistic regression (LR) and supervised machine learning (ML) approaches were used for variable selection. The backward LR method and seven ML algorithms were applied to train and test the prediction models. The best model was identified based on model performance, fitting criteria, area under the receiver operating characteristic curve (AUROC), risk probability cut-off points, and clinical relevance.
resultsThe statistical 12-parameter model demonstrated excellent performance (AUROC = 0.89, sensitivity = 0.91, specificity = 0.75) and strong discrimination ability for risk probability prediction (AUROC = 0.78, cut-off = 0.46), outperforming other ML models. In the final best model: the baseline risk probability of QTc prolongation was 0.13, even in the absence of other contributing factors. Baseline QTc prolongation and a history of cardiovascular disease (excluding arrhythmia, cardiomyopathy, etc.) contributed the most to incremental risk probability (0.471 and 0.282, respectively), after controlling for other factors. The remaining 10 factors each contributed to an increased probability of QTc prolongation for more than 0.14 probability.
conclusionsA logistic regression model utilizing 12 easily accessible variables from EMRs outperformed ML models in predicting the risk probability of QTc prolongation in cancer patients newly treated with five oral TKIs. These findings serve as a valuable clinical reference for integrating digital monitoring into cardiovascular care for cancer survivors undergoing targeted therapy with TKIs. They also underscore the importance of screening baseline ECG before initiating TKIs to assess the risk of QTc prolongation, facilitating early intervention and prevention in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.